New cocktail of drugs aims to tackle rare brain cancer

NCT ID NCT07185373

Not yet recruiting Disease control Sponsor: Huashan Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This trial is testing whether adding a targeted drug called orelabrutinib to standard chemotherapy can improve outcomes for people newly diagnosed with primary central nervous system lymphoma, a rare type of brain cancer. About 215 participants will be randomly assigned to one of three treatment groups. The study is not yet recruiting and is in phase 2/3.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Orelabrutinib, teniposide, rituximab, methotrexate, dexamethasone
What this could lead to: If successful, this could offer a more effective first-line treatment for primary CNS lymphoma, potentially improving remission rates and delaying progression.
What could go wrong: This is an early-to-mid-stage trial (phase 2/3) with a relatively small sample size. The drug combination may cause significant side effects, and it is not yet known if it will outperform existing therapies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma primary central nervous system lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA

Contacts and locations

Locations

Department of Hematology, Qilu Hospital of Shandong University

Jinan, China
West China Hospital of Sichuan University

Chengdu, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.